NCT07065279View on ClinicalTrials.gov

JY231(JY231) Injection for the Treatment of R/R B-cell Malignancies

NARecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
B-cell Malignancies
Interventions
DRUG

JY231 Injection

Patients were enrolled and given a single dose of JY231 injection intravenously, hospitalized for observation over the following month, and followed up for observation over the following 2 years.

Trial Locations (1)

Unknown

RECRUITING

920th HJointLogistics, Kunming

All Listed Sponsors
lead

920th Hospital of Joint Logistics Support Force of People's Liberation Army of China

OTHER